Functional liquid biopsy test for tumour diagnosis and surveillance (FLUID-C)

Description

A large number of studies have shown that extracellular vesicles (EVs) derived from cancer cells promote cancer progression by activating different signalling pathways in target cells. In this project, we propose to develop a conceptually novel liquid biopsy method for cancer detection and monitoring based on gene expression changes induced in target cells by EVs in the patient's blood. In this one-year project, we plan to develop a proof-of-concept of this technology for the diagnosis of breast cancer (BC).

A key component of the proposed technology will be a cell line that acts as a biosensor - i.e. it can sense the patient's EVs and respond to them with specific changes in gene expression. The main research objective of the FLUID-C project is to establish a fibroblast cell line that would serve as a sensitive EV biosensor and to identify gene expression signatures that are specifically induced by EVs from CF patients but not from healthy individuals.

Key commercialisation activities will include the development of an IP management strategy, a detailed commercialisation roadmap, the identification of potential industry partners and targeted communication activities, thus mapping out a clear path to market.

Achievable results

To obtain proof-of-concept for the FLUID-C technology, using breast cancer diagnostics as an example, thus reaching TRL3, and to develop a roadmap for bringing this technology to market.

Benefit

Blood analysis for breast cancer diagnosis and early detection of recurrence, facilitating early detection and post-operative monitoring, thus improving the effectiveness of treatment and quality of life for patients.